Use of risperidone in pervasive developmental disorders: A case series

被引:66
作者
Fisman, S
Steele, M
机构
[1] Div. of Child and Adol. Psychiatry, London Health Sciences Centre, University of Western Ontario, London, Ont.
[2] Div. of Child and Adol. Psychiatry, London Health Sciences Centre, London, Ont. N6C 2V5, 6 N., Phase I
关键词
D O I
10.1089/cap.1996.6.177
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
A series of 14 children and adolescents (ages 9-17 years, 10 males) were treated with risperidone for pervasive developmental disorder. The rationale for using an atypical neuroleptic agent is based on its ability to target both positive and negative symptoms of schizophrenia. It was postulated that symptoms similar to the positive and negative symptoms of schizophrenia may be observed in the pervasive developmental disorders and might respond favorably to risperidone. Twelve of the 14 youths had been treated previously with several psychotropic drugs, often concurrently. Risperidone was initiated at a starting dose of 0.25 mg twice daily and increased in 0.25 mg/day increments every 5-7 days. Optimal dosages ranged from 0.75 to 1.5 mg daily in divided doses. Thirteen of the 14 youths appeared to benefit from risperidone. Improvement in functionality on the Children's Global Assessment Scale was demonstrated in 13 of 14 cases. Disruptive behaviors, when present, markedly decreased on risperidone. Ten patients showed a marked reduction in agitation and anxiety. Social awareness improved markedly in 10 patients, moderately in 3, and only slightly in 1. All but 1 patient demonstrated a lessening in obsessional behaviors. Effects on attention were uniformly positive. Side effects were minimal at the dosages used in this study; 5 patients had initial sedation. Neither extrapyramidal side effects nor agitation was observed in any case. Ten of 14 youths could be managed with risperidone monotherapy. During the follow-up period (mean 7 months), none of the patients experienced a major relapse while taking risperidone. Positive and negative symptoms, as typically characterized in schizophrenia, were both found to improve equally well with risperidone treatment. Based on these findings, a prospective clinical trial with a randomized controlled design is warranted.
引用
收藏
页码:177 / 190
页数:14
相关论文
共 68 条
[1]   ELEVATED BLOOD SEROTONIN IN AUTISTIC PROBANDS AND THEIR 1ST-DEGREE RELATIVES [J].
ABRAMSON, RK ;
WRIGHT, HH ;
CARPENTER, R ;
BRENNAN, W ;
LUMPUY, O ;
COLE, E ;
YOUNG, SR .
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 1989, 19 (03) :397-407
[2]   PARANOID AND AGGRESSIVE-BEHAVIOR IN 2 OBSESSIVE-COMPULSIVE ADOLESCENTS TREATED WITH CLOMIPRAMINE [J].
ALARCON, RD ;
JOHNSON, BR ;
LUCAS, JP .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1991, 30 (06) :999-1002
[3]   CLOZAPINE-INDUCED AGRANULOCYTOSIS - INCIDENCE AND RISK-FACTORS IN THE UNITED-STATES [J].
ALVIR, JMJ ;
LIEBERMAN, JA ;
SAFFERMAN, AZ ;
SCHWIMMER, JL ;
SCHAAF, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03) :162-167
[4]  
ANDERSON GM, 1987, MED BIOL, V65, P67
[5]   WHOLE-BLOOD SEROTONIN IN AUTISTIC AND NORMAL SUBJECTS [J].
ANDERSON, GM ;
FREEDMAN, DX ;
COHEN, DJ ;
VOLKMAR, FR ;
HODER, EL ;
MCPHEDRAN, P ;
MINDERAA, RB ;
HANSEN, CR ;
YOUNG, JG .
JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY AND ALLIED DISCIPLINES, 1987, 28 (06) :885-900
[6]  
ANDERSON LT, 1984, AM J PSYCHIAT, V141, P1195
[7]  
Andreasen N, 1984, SCALE ASSESSMENT POS
[8]  
ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P789
[9]  
Association AP, 2000, DIAGNOSTIC STAT MANU, DOI [10.1176/appi.books.9780890423349, DOI 10.1176/APPI.BOOKS.9780890425596]
[10]   DOSING OF ANTIPSYCHOTIC AGENTS IN PEDIATRIC POPULATIONS [J].
BALDESSARINI, RJ ;
TEICHER, MH .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 1995, 5 (01) :1-4